Published in Am J Pathol on September 01, 2003
Association of large intergenic noncoding RNA expression with disease activity and organ damage in systemic lupus erythematosus. Arthritis Res Ther (2015) 1.49
The role of the oncofetal H19 lncRNA in tumor metastasis: orchestrating the EMT-MET decision. Oncotarget (2016) 1.05
The increasing complexity of the oncofetal h19 gene locus: functional dissection and therapeutic intervention. Int J Mol Sci (2013) 1.03
PBMC and exosome-derived Hotair is a critical regulator and potent marker for rheumatoid arthritis. Clin Exp Med (2014) 0.95
Reduced MiR-675 in exosome in H19 RNA-related melanogenesis via MITF as a direct target. J Invest Dermatol (2013) 0.87
Could lncRNAs be the missing links in control of mesenchymal stem cell differentiation? J Cell Physiol (2015) 0.85
LncRNAs in pancreatic cancer. Oncotarget (2016) 0.80
Characters, functions and clinical perspectives of long non-coding RNAs. Mol Genet Genomics (2016) 0.79
Functional diversity of long non-coding RNAs in immune regulation. Genes Dis (2016) 0.79
Microarray Analysis of lncRNA and mRNA Expression Profiles in Patients with Neuromyelitis Optica. Mol Neurobiol (2016) 0.78
Environmental Health and Long Non-coding RNAs. Curr Environ Health Rep (2016) 0.76
Review: Long Noncoding RNAs in the Regulation of Inflammatory Pathways in Rheumatoid Arthritis and Osteoarthritis. Arthritis Rheumatol (2016) 0.76
Immunopathogenesis of systemic lupus erythematosus and rheumatoid arthritis: The role of aberrant expression of non-coding RNAs in T cells. Clin Exp Immunol (2016) 0.75
Integrated Analysis of LncRNA-mRNA Co-Expression Profiles in Patients with Moyamoya Disease. Sci Rep (2017) 0.75
Transcriptional profiling identifies differential expression of long non-coding RNAs in Jo-1 associated and inclusion body myositis. Sci Rep (2017) 0.75
Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry (1979) 180.95
The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum (1988) 111.05
Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum (1986) 29.12
Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J Biol Chem (1998) 13.93
Multipotent mesenchymal stem cells from adult human synovial membrane. Arthritis Rheum (2001) 4.57
Macrophages in rheumatoid arthritis. Arthritis Res (2000) 3.40
Wortmannin inactivates phosphoinositide 3-kinase by covalent modification of Lys-802, a residue involved in the phosphate transfer reaction. Mol Cell Biol (1996) 3.08
Tumour-suppressor activity of H19 RNA. Nature (1993) 3.06
Somatic mutations in the p53 tumor suppressor gene in rheumatoid arthritis synovium. Proc Natl Acad Sci U S A (1997) 2.80
Epigenetic lesions at the H19 locus in Wilms' tumour patients. Nat Genet (1994) 2.29
Evidence for impaired T cell DNA methylation in systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum (1990) 2.27
Dominant-negative p53 mutations in rheumatoid arthritis. Arthritis Rheum (1999) 2.18
Rheumatoid arthritis and p53: how oxidative stress might alter the course of inflammatory diseases. Immunol Today (2000) 2.03
Retrotransposable L1 elements expressed in rheumatoid arthritis synovial tissue: association with genomic DNA hypomethylation and influence on gene expression. Arthritis Rheum (2000) 2.01
Mononuclear phagocytes and rheumatoid synovitis. Mastermind or workhorse in arthritis? Arthritis Rheum (1997) 1.89
Expression and function of wingless and frizzled homologs in rheumatoid arthritis. Proc Natl Acad Sci U S A (2000) 1.81
Activation of synovial fibroblasts in rheumatoid arthritis: lack of Expression of the tumour suppressor PTEN at sites of invasive growth and destruction. Arthritis Res (2000) 1.73
Overexpression of an ectopic H19 gene enhances the tumorigenic properties of breast cancer cells. Carcinogenesis (2002) 1.69
Apoptosis in rheumatoid arthritis: p53 overexpression in rheumatoid arthritis synovium. Am J Pathol (1996) 1.65
Isolation and characterization of rheumatoid arthritis synovial fibroblasts from primary culture--primary culture cells markedly differ from fourth-passage cells. Arthritis Res (2000) 1.62
Regulation of joint destruction and inflammation by p53 in collagen-induced arthritis. Am J Pathol (2002) 1.58
Non-coding, mRNA-like RNAs database Y2K. Nucleic Acids Res (2000) 1.57
Regulatory RNAs. Cell Mol Life Sci (2001) 1.56
Expression of sentrin, a novel antiapoptotic molecule, at sites of synovial invasion in rheumatoid arthritis. Arthritis Rheum (2000) 1.54
The imprinted H19 gene is a marker of early recurrence in human bladder carcinoma. Mol Pathol (2000) 1.41
Pathogenesis of rheumatoid arthritis: the role of synoviocytes. Rheum Dis Clin North Am (2001) 1.30
Regulation of synoviocyte proliferation, apoptosis, and invasion by the p53 tumor suppressor gene. Am J Pathol (1998) 1.26
Possible physiological role of H19 RNA. Mol Carcinog (2002) 1.22
Evidence for evolutionarily conserved secondary structure in the H19 tumor suppressor RNA. Nucleic Acids Res (2000) 1.20
The product of the imprinted H19 gene is an oncofetal RNA. Mol Pathol (1997) 1.15
Expression of the imprinted gene H19 in the human fetus. Mol Reprod Dev (1994) 1.14
Drug-induced DNA hypermethylation and drug resistance in human tumors. Cancer Res (1989) 1.08
Molecular evolutionary evidence that H19 mRNA is functional. Trends Genet (1999) 1.07
The stressed synovium. Arthritis Res (2001) 1.07
The H19 TATA-less promoter is efficiently repressed by wild-type tumor suppressor gene product p53. Oncogene (1998) 1.05
Activation of synovial fibroblasts in rheumatoid arthritis. Ann Rheum Dis (1995) 1.03
Steroid hormones modulate H19 gene expression in both mammary gland and uterus. Oncogene (1999) 1.03
The expression of the H-19 and IGF-2 genes during human embryogenesis and placental development. Mol Reprod Dev (1993) 1.02
Alterations of the 11p15 imprinted region and the IGFs system in a case of recurrent non-islet-cell tumour hypoglycaemia (NICTH). Clin Endocrinol (Oxf) (2000) 1.01
5-Methylcytosine content of DNA in blood, synovial mononuclear cells and synovial tissue from patients affected by autoimmune rheumatic diseases. J Chromatogr (1991) 1.00
Artherosclerosis as an infectious, inflammatory and autoimmune disease. Trends Immunol (2001) 0.99
Imprinted H19 gene expression in embryogenesis and human cancer: the oncofetal connection. Am J Med Genet (2000) 0.98
H19, a marker of developmental transition, is reexpressed in human atherosclerotic plaques and is regulated by the insulin family of growth factors in cultured rabbit smooth muscle cells. J Clin Invest (1996) 0.95
DNA hypomethylation in inflammatory arthritis: reversal with methotrexate. J Lab Clin Med (1996) 0.94
Human imprinted genes as oncodevelopmental markers. Tumour Biol (1994) 0.94
Expression and parental imprinting of the H19 gene in human rhabdomyosarcoma. Oncogene (1997) 0.93
Imprinting and expression of insulin-like growth factor-II and H19 in normal breast tissue and breast tumor. J Clin Endocrinol Metab (1996) 0.90
Cross-talk between mesenchyme and epithelium increases H19 gene expression during scattering and morphogenesis of epithelial cells. Exp Cell Res (2002) 0.88
Rheumatoid arthritis. Curr Opin Rheumatol (2001) 0.86
Mosaic chromosomal aberrations in synovial fibroblasts of patients with rheumatoid arthritis, osteoarthritis, and other inflammatory joint diseases. Arthritis Res (2001) 0.86
Growth signaling in breast cancer cells: outcomes and promises of proteomics. Biochem Pharmacol (2002) 0.85
H19 and insulin-like growth factor-II gene expression in adrenal tumors and cultured adrenal cells. J Clin Endocrinol Metab (1995) 0.84
Imprinted genes are up-regulated by growth arrest in embryonic fibroblasts. J Biochem (1997) 0.83
H19 gene overexpression in atypical multidrug-resistant cells associated with expression of a 95-kilodalton membrane glycoprotein. Cancer Res (1996) 0.81
Methylation status within exon 3 of the c-myc gene as a prognostic marker in myeloma and leukaemia. Leuk Res (1993) 0.80
A new double labeling technique for combined in situ hybridization and immunohistochemical analysis. Lab Invest (1994) 0.80
Mutation detection in mosaic situations: RNA mismatch assay and denaturing gradient gel electrophoresis are more sensitive than conventional cycle sequencing. Anal Biochem (2001) 0.79
Molecular basis of elevated c-myb expression in the abnormal L3T4-, Lyt-2- T lymphocytes of autoimmune mice. J Immunol (1987) 0.78
Interferon-a sensitivity in melanoma cells: detection of potential response marker genes. Recent Results Cancer Res (2002) 0.76
[Changes in methylation of tumor cells: a new in situ quantitative approach on interphase nuclei and chromosomes]. Bull Cancer (1995) 0.76
2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum (2010) 18.82
2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis (2010) 12.12
5S Ribosomal RNA Database. Nucleic Acids Res (2002) 5.95
Validation of a prediction rule for disease outcome in patients with recent-onset undifferentiated arthritis: moving toward individualized treatment decision-making. Arthritis Rheum (2008) 2.83
Design of antisense oligonucleotides stabilized by locked nucleic acids. Nucleic Acids Res (2002) 2.58
TGF-beta and fibrosis in different organs - molecular pathway imprints. Biochim Biophys Acta (2009) 2.44
A novel ultrasonographic synovitis scoring system suitable for analyzing finger joint inflammation in rheumatoid arthritis. Arthritis Rheum (2005) 2.36
Cytomegalovirus (CMV) phosphoprotein 65 makes a large contribution to shaping the T cell repertoire in CMV-exposed individuals. J Infect Dis (2002) 2.33
Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum (2005) 2.32
Correlation between circulating CD27high plasma cells and disease activity in patients with systemic lupus erythematosus. Arthritis Rheum (2003) 2.32
Vascular receptor autoantibodies in pulmonary arterial hypertension associated with systemic sclerosis. Am J Respir Crit Care Med (2014) 2.16
Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study. Arthritis Res Ther (2008) 2.15
The role of biosimilars in the treatment of rheumatic diseases. Ann Rheum Dis (2012) 2.03
The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: Phase 2 methodological report. Arthritis Rheum (2010) 1.94
Local RNA target structure influences siRNA efficacy: systematic analysis of intentionally designed binding regions. J Mol Biol (2005) 1.86
Involvement of functional autoantibodies against vascular receptors in systemic sclerosis. Ann Rheum Dis (2010) 1.83
Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res Ther (2006) 1.82
EULAR recommendations for terminology and research in individuals at risk of rheumatoid arthritis: report from the Study Group for Risk Factors for Rheumatoid Arthritis. Ann Rheum Dis (2012) 1.78
A prospective time-course study on serological testing for human immunodeficiency virus, hepatitis B virus and hepatitis C virus with blood samples taken up to 48 h after death. J Med Microbiol (2011) 1.77
Remission and rheumatoid arthritis: data on patients receiving usual care in twenty-four countries. Arthritis Rheum (2008) 1.76
Ten years of clinical results with a tissue-engineered pulmonary valve. Ann Thorac Surg (2011) 1.70
Identification of modifications in microbial, native tRNA that suppress immunostimulatory activity. J Exp Med (2012) 1.57
Application of locked nucleic acids to improve aptamer in vivo stability and targeting function. Nucleic Acids Res (2004) 1.54
Mid-term clinical results using a tissue-engineered pulmonary valve to reconstruct the right ventricular outflow tract during the Ross procedure. Ann Thorac Surg (2007) 1.50
The role of B cells in rheumatoid arthritis: mechanisms and therapeutic targets. Curr Opin Rheumatol (2003) 1.49
Heterozygous Arg753Gln polymorphism of human TLR-2 impairs immune activation by Borrelia burgdorferi and protects from late stage Lyme disease. J Immunol (2005) 1.49
The association between rheumatoid arthritis and periodontal disease. Arthritis Res Ther (2010) 1.47
Diminished peripheral blood memory B cells and accumulation of memory B cells in the salivary glands of patients with Sjögren's syndrome. Arthritis Rheum (2002) 1.47
Treatment of posttraumatic and focal osteoarthritic cartilage defects of the knee with autologous polymer-based three-dimensional chondrocyte grafts: 2-year clinical results. Arthritis Res Ther (2007) 1.45
Autoregulation of Th1-mediated inflammation by twist1. J Exp Med (2008) 1.43
Comparison of different antisense strategies in mammalian cells using locked nucleic acids, 2'-O-methyl RNA, phosphorothioates and small interfering RNA. Nucleic Acids Res (2003) 1.42
Inflammation assessment in patients with arthritis using a novel in vivo fluorescence optical imaging technology. Ann Rheum Dis (2012) 1.39
Delays in assessment of patients with rheumatoid arthritis: variations across Europe. Ann Rheum Dis (2011) 1.39
Probing the SELEX process with next-generation sequencing. PLoS One (2011) 1.34
Rheumatoid factor revisited. Curr Opin Rheumatol (2004) 1.33
Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions. Ann Rheum Dis (2012) 1.33
B-cell-directed therapies for autoimmune disease. Nat Rev Rheumatol (2009) 1.32
A new frontier for molecular medicine: noncoding RNAs. Biochim Biophys Acta (2005) 1.31
Epratuzumab (humanised anti-CD22 antibody) in primary Sjögren's syndrome: an open-label phase I/II study. Arthritis Res Ther (2006) 1.30
Constitutive upregulation of the transforming growth factor-beta pathway in rheumatoid arthritis synovial fibroblasts. Arthritis Res Ther (2007) 1.29
Noncoding regulatory RNAs database. Nucleic Acids Res (2003) 1.29
Reproducibility of allergen, endotoxin and fungi measurements in the indoor environment. J Expo Anal Environ Epidemiol (2003) 1.27
5 S rRNA: structure and interactions. Biochem J (2003) 1.20
Human platelet-rich plasma stimulates migration and chondrogenic differentiation of human subchondral progenitor cells. J Orthop Res (2011) 1.19
Relative percentage and zonal distribution of mesenchymal progenitor cells in human osteoarthritic and normal cartilage. Arthritis Res Ther (2011) 1.19
Identification of dialysis patients with panel-reactive memory T cells before kidney transplantation using an allogeneic cell bank. J Am Soc Nephrol (2006) 1.18
A frequent functional toll-like receptor 7 polymorphism is associated with accelerated HIV-1 disease progression. AIDS (2009) 1.18
Certolizumab pegol plus methotrexate provides broad relief from the burden of rheumatoid arthritis: analysis of patient-reported outcomes from the RAPID 2 trial. Ann Rheum Dis (2011) 1.17
The US7 score is sensitive to change in a large cohort of patients with rheumatoid arthritis over 12 months of therapy. Ann Rheum Dis (2012) 1.16
New approaches of B-cell-directed therapy: beyond rituximab. Curr Opin Rheumatol (2008) 1.16
A streamlined protocol for emulsion polymerase chain reaction and subsequent purification. Anal Biochem (2010) 1.15
Rapid and sustained improvements in health-related quality of life, fatigue, and other patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: results from the RAPID 1 randomized controlled trial. Arthritis Res Ther (2009) 1.14
RNA cleaving '10-23' DNAzymes with enhanced stability and activity. Nucleic Acids Res (2003) 1.14
Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement. Ann Rheum Dis (2012) 1.13
Comparative study of DNA enzymes and ribozymes against the same full-length messenger RNA of the vanilloid receptor subtype I. J Biol Chem (2001) 1.13
Effect of Nigella sativa (black seed) on subjective feeling in patients with allergic diseases. Phytother Res (2003) 1.12
Porcine mesenchymal stem cells. Induction of distinct mesenchymal cell lineages. Cell Tissue Res (2002) 1.10
CCR5Delta32 genotypes in a German HIV-1 seroconverter cohort and report of HIV-1 infection in a CCR5Delta32 homozygous individual. PLoS One (2008) 1.10
Cellular uptake and localization of a Cy3-labeled siRNA specific for the serine/threonine kinase Pim-1. Oligonucleotides (2003) 1.10
High-level serum B-cell activating factor and promoter polymorphisms in patients with idiopathic thrombocytopenic purpura. Br J Haematol (2006) 1.10
Immunopathologic role of B lymphocytes in rheumatoid arthritis: rationale of B cell-directed therapy. Autoimmun Rev (2006) 1.09
Silencing of vanilloid receptor TRPV1 by RNAi reduces neuropathic and visceral pain in vivo. Biochem Biophys Res Commun (2006) 1.09
Noncoding RNAs database (ncRNAdb). Nucleic Acids Res (2006) 1.08
The first crystal structure of an RNA racemate. Acta Crystallogr D Biol Crystallogr (2006) 1.08
Sequence requirements in the catalytic core of the "10-23" DNA enzyme. J Biol Chem (2002) 1.08
Coexistence of autoantibodies and alloantibodies to red blood cells due to blood transfusion. Transfusion (2007) 1.08
Abnormalities in peripheral B cell memory of patients with primary Sjögren's syndrome. Arthritis Rheum (2004) 1.08
Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). J Rheumatol (2008) 1.05
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012. Ann Rheum Dis (2013) 1.05
Detailed analysis of the variability of peptidylarginine deiminase type 4 in German patients with rheumatoid arthritis: a case-control study. Arthritis Res Ther (2006) 1.05
Tissue-specific up-regulation of the proteasome subunit beta5i (LMP7) in Sjögren's syndrome. Arthritis Rheum (2006) 1.05
After treat-to-target: can a targeted ultrasound initiative improve RA outcomes? Ann Rheum Dis (2012) 1.04
Decrease in expression of bone morphogenetic proteins 4 and 5 in synovial tissue of patients with osteoarthritis and rheumatoid arthritis. Arthritis Res Ther (2006) 1.04
The Nano-tag, a streptavidin-binding peptide for the purification and detection of recombinant proteins. Protein Expr Purif (2004) 1.03
Decellularized xenogenic heart valves reveal remodeling and growth potential in vivo. Tissue Eng (2006) 1.03
Real-world effectiveness of abatacept for rheumatoid arthritis treatment in European and Canadian populations: a 6-month interim analysis of the 2-year, observational, prospective ACTION study. BMC Musculoskelet Disord (2014) 1.03
Cytokine mRNA and protein expression in primary-culture and repeated-passage synovial fibroblasts from patients with rheumatoid arthritis. Arthritis Res (2001) 1.01
Bronchoalveoloar lavage fluid cytokines and chemokines as markers and predictors for the outcome of interstitial lung disease in systemic sclerosis patients. Arthritis Res Ther (2009) 1.01
An open-label pilot study of the effectiveness of adalimumab in patients with rheumatoid arthritis and previous infliximab treatment: relationship to reasons for failure and anti-infliximab antibody status. Clin Rheumatol (2008) 1.00
Identification of intra-group, inter-individual, and gene-specific variances in mRNA expression profiles in the rheumatoid arthritis synovial membrane. Arthritis Res Ther (2008) 1.00
Investigation of TRPV1 loss-of-function phenotypes in transgenic shRNA expressing and knockout mice. Mol Cell Neurosci (2007) 0.99
Validation of the Serological Testing for Anti-HIV-1/2, Anti-HCV, HBsAg, and Anti-HBc from Post-mortem Blood on the Siemens-BEP-III Automatic System. Transfus Med Hemother (2011) 0.99
A DNA aptamer with high affinity and specificity for therapeutic anthracyclines. Anal Biochem (2007) 0.98
Improvements in health-related quality of life after treatment with tocilizumab in patients with rheumatoid arthritis refractory to tumour necrosis factor inhibitors: results from the 24-week randomized controlled RADIATE study. Rheumatology (Oxford) (2012) 0.98
Antibodies against PM/Scl-75 and PM/Scl-100 are independent markers for different subsets of systemic sclerosis patients. Arthritis Res Ther (2009) 0.98
EULAR definition of erosive disease in light of the 2010 ACR/EULAR rheumatoid arthritis classification criteria. Ann Rheum Dis (2013) 0.97
Gene expression profiling of rheumatoid arthritis synovial cells treated with antirheumatic drugs. J Biomol Screen (2007) 0.97
Searching sequence space for high-affinity binding peptides using ribosome display. J Mol Biol (2003) 0.97
Allogenic versus autologous cancellous bone in lumbar segmental spondylodesis: a randomized prospective study. Eur Spine J (2009) 0.95
Batch correction of microarray data substantially improves the identification of genes differentially expressed in rheumatoid arthritis and osteoarthritis. BMC Med Genomics (2012) 0.95
A practical concept for preoperative identification of patients with impaired primary hemostasis. Clin Appl Thromb Hemost (2004) 0.95
Gaining target access for deoxyribozymes. J Mol Biol (2004) 0.95
Selection of RNA aptamers to the Alzheimer's disease amyloid peptide. Biochem Biophys Res Commun (2002) 0.95
IL-33 regulates TNF-α dependent effects in synovial fibroblasts. Int J Mol Med (2012) 0.95
Intra-articular injections of high-molecular-weight hyaluronic acid have biphasic effects on joint inflammation and destruction in rat antigen-induced arthritis. Arthritis Res Ther (2005) 0.94